2 news items
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
with this cancer type.1 Historically, depending on induction regimens and mobilization strategies, approximately 50
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
regimens and mobilization strategies, approximately 50% to 75% of patients required more than one apheresis session to collect a target number
- Prev
- 1
- Next